Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
4.99 CAD 0.02 ( 0.40%)
Last update at 2026-11-04T20:44:00Z
VOLUME
14499
Market Cap
125.97M

Momentum Score

…

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.92
Low
5.06
High
52 Week Price Range
2.47
Low
4.16
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Medexus Pharmaceuticals Inc is a commercial-stage specialty pharmaceutical company listed on the TSX that acquires, licenses and markets prescription medicines and medical products primarily in Canada and selected international markets. Its long-term growth may be supported by product launches, licensing and distribution agreements and targeted acquisitions that could expand recurring revenue, which may appeal to investors seeking exposure to niche pharmaceutical commercialization.

Key investment risks include reliance on a concentrated product portfolio and third-party licensing partners, regulatory and reimbursement changes, and execution risk from integrating acquisitions or launching new products.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.97
Dividend Yield
-
Revenue TTM
99.43M
Revenue Per Share
3.14
Gross Profit TTM
62.99M
Debt / Equity
1.65
ROE
-0.64%
Net Debt
13.21M
ROCE
12.93%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 1.44M 0.11M -5.04M -3.82M -31.50M
Net income 2.25M -0.21M 1.22M -2.88M -28.26M
Selling general administrative 28.35M 27.86M 36.86M 34.52M 19.28M
Selling and marketing expenses 7.80M 10.58M 11.39M 9.51M 16.89M
Gross profit 56.58M 59.51M 60.04M 37.93M 42.01M
Reconciled depreciation 7.18M 5.81M 6.08M 6.14M 5.98M
Ebit 9.63M 10.76M 6.52M -13.94M -1.19M
Ebitda 16.81M 18.59M 14.57M -6.23M 6.71M
Depreciation and amortization 7.18M 7.83M 8.05M 7.71M 7.90M
Operating income 8.22M 10.79M 7.61M -15.00M -1.38M
Other operating expenses 100.11M 100.27M 99.61M 89.08M 78.93M
Interest expense 8.20M 13.36M 13.61M 12.22M 9.82M
Tax provision -0.81M 0.32M -6.26M -0.94M -3.24M
Interest income 6.78M - 12.65M 11.18M 0.00M
Net interest income -8.20M -13.36M -13.61M -12.22M -9.82M
Income tax expense -0.81M 0.32M -6.26M -0.94M -3.24M
Total revenue 108.33M 113.05M 108.10M 76.70M 79.66M
Total operating expenses 48.36M 46.73M 51.55M 50.30M 41.27M
Cost of revenue 51.75M 53.54M 48.06M 38.77M 37.66M
Total other income expense net -6.78M 0.68M 0.08M 20.78M -22.42M
Net income from continuing ops 2.25M -0.21M 1.22M -2.88M -28.26M
Net income applicable to common shares 2.25M - 1.22M -2.88M -28.26M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 171.84M 155.73M 161.33M 139.22M 148.51M
Intangible assets 71.60M 64.14M 70.37M 76.56M 76.36M
Other current assets 0.38M 2.30M 2.29M 1.28M 1.67M
Total liab 119.69M 125.41M 138.88M 121.43M 130.50M
Total stockholder equity 52.14M 30.32M 22.45M 17.79M 18.02M
Other current liab 0.12M 2.70M 7.38M 3.89M 2.04M
Common stock 96.10M 76.39M 69.01M 68.69M 66.69M
Capital stock 96.10M 76.39M 69.01M 68.69M 66.69M
Retained earnings -61.99M -64.24M -64.03M -65.25M -62.37M
Other liab - - 28.01M 33.51M 56.26M
Good will 10.00M 10.28M 10.28M 10.69M 10.65M
Other assets 8.98M - 6.81M 1.64M 2.13M
Cash 23.97M 5.25M 13.07M 10.02M 18.70M
Cash and equivalents 23.97M - 13.07M 10.02M 18.70M
Total current liabilities 97.31M 66.23M 83.50M 48.11M 39.94M
Current deferred revenue - 40.03M - - -
Net debt 13.21M 44.64M 57.01M 44.84M 26.17M
Short term debt 0.00M 15.74M 0.00M 0.00M 0.00M
Short long term debt 36.98M 15.74M 42.71M 15.05M 10.57M
Short long term debt total - 49.90M - - 34.30M
Other stockholder equity 6.03M 12.01M 6.16M 3.97M 4.20M
Property plant equipment 0.69M - 0.90M 1.22M 0.80M
Total current assets 80.57M 72.50M 72.97M 49.11M 58.57M
Net tangible assets - - -58.21M -69.46M -69.00M
Net receivables 13.17M 24.03M 22.38M 14.41M 18.83M
Long term debt 0.20M 34.15M 27.38M 39.82M 34.30M
Inventory 35.29M 30.77M 22.85M 21.35M 14.67M
Accounts payable 5.73M 7.75M 33.41M 12.05M 14.86M
Accumulated other comprehensive income - 6.17M - - -
Non currrent assets other - - - 1.64M 2.13M
Non current assets total 91.27M 83.24M 88.36M 90.11M 89.94M
Long term debt total 0.20M - 27.38M 39.82M 34.30M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -6.00M -3.48M -1.72M -8.20M -11.70M
Change to liabilities - - 4.75M 3.60M 4.62M
Total cashflows from investing activities -6.00M - -1.72M -8.20M -11.71M
Net borrowings -14.24M - 10.73M 3.73M -0.02M
Total cash from financing activities 0.80M -23.05M 6.41M 0.66M 18.68M
Change to operating activities - - -9.79M 3.35M -0.93M
Net income 2.25M -0.21M 1.22M -2.88M -28.26M
Change in cash 18.72M -7.81M 3.05M -8.69M 13.47M
Begin period cash flow 5.25M 13.07M 10.02M 18.70M 5.23M
End period cash flow 23.97M 5.25M 13.07M 10.02M 18.70M
Total cash from operating activities 24.03M 18.71M -1.44M -1.18M 5.04M
Issuance of capital stock 19.16M 7.61M 0.00M 0.00M 22.64M
Depreciation 7.18M 5.81M 6.08M 6.14M 5.98M
Other cashflows from investing activities -2.54M - -1.36M -0.48M 0.00M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory -4.60M -6.75M -1.99M -6.66M -0.01M
Change to account receivables 10.54M -1.68M -8.24M 4.43M -3.50M
Sale purchase of stock 19.30M - - 0.00M 22.64M
Other cashflows from financing activities -4.13M -3.48M 31.13M 0.83M -3.58M
Change to netincome - - 6.52M -9.18M 27.14M
Capital expenditures 2.73M 0.27M 0.36M 7.71M 10.76M
Change in working capital 5.84M 2.34M -15.26M 4.73M 0.18M
Stock based compensation 0.41M 0.47M 1.22M 1.88M 1.27M
Other non cash items 9.16M 10.61M 11.56M -10.12M 29.11M
Free cash flow 21.31M 18.45M -1.81M -8.89M -5.72M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MDP
Medexus Pharmaceuticals Inc		 0.02
0.40%		 4.99 - 5.43 1.27 1.76 1.03 6.47
CURA
Curaleaf Holdings Inc.		 -0.74
5.20%		 13.49 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.31
2.72%		 11.72 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.16
3.36%		 4.92 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.41
11.02%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

10 King Street East, Toronto, ON, Canada, M5C 1C3

877 422 5242

https://www.medexus.com

91

Name Title Year Born
Mr. Kenneth d'Entremont CEO & Director NA
Mr. Marcel Konrad Chief Financial Officer 1976
Mr. Michael David Adelman Gen. Mang., U.S. Operations 1971
Ms. Tina Byers CFA Exec. of Investor Relations NA
Mr. Ian C. Wildgoose Brown Gen. Counsel & Corp. Sec. NA
Mr. Bill Poncy Sr. VP of Commercial Operations - United States NA
Mr. Brian Peters VP of Sales & Marketing - United States NA
Mr. Richard Labelle Chief Operating Officer NA
Mr. Ian C. Wildgoose Brown General Counsel & Corporate Secretary NA
Mr. Brendon Buschman Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…